Updated: June 5, 2021 10:09:02 am
The 4-1 vote by Anvisa’s board follows rulings in April to reject Brazilian states’ request for Sputnik V due to a lack of data guaranteeing its safety, quality and effectiveness, and in March to reject Covaxin because it did not meet Anvisa’s manufacturing standards.
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.